- Home
- JANX vs HBNC Comparison
JANX vs HBNC Comparison
Compare JANX & HBNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JANX | HBNC |
|---|---|---|
| Founded | 2017 | 1873 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.3M | 962.4M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | JANX | HBNC |
|---|---|---|
| Price | $16.07 | $20.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $47.00 | $21.00 |
| AVG Volume (30 Days) | ★ 1.5M | 838.5K |
| Earning Date | 05-08-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 3.57% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.51 |
| Revenue | ★ $10,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.52 |
| P/E Ratio | ★ N/A | $40.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.12 | $14.84 |
| 52 Week High | $35.34 | $20.66 |
Technical Indicators
Market Signals| Indicator | JANX | HBNC |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 62.02 |
| Support Level | $13.21 | $17.07 |
| Resistance Level | $16.75 | $20.51 |
| Average True Range (ATR) | 0.66 | 0.40 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 63.70 | 83.67 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.